Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05816122 · ClinicalTrials.gov registry record · NA

MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect

A NA study of Multiple Sclerosis, sponsored by Ad scientiam.

Active
Registry status
NA
Development phase
336
Enrollment target
20
Study locations

NCT05816122: Active NA study of Multiple Sclerosis, sponsored by Ad scientiam.

NCT05816122 is a NA study of Multiple Sclerosis that is active but no longer recruiting, run by Ad scientiam. The registered enrollment target is 336 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05816122, a NA study of Multiple Sclerosis, is active but no longer recruiting, sponsored by Ad scientiam.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
336 participants
Enrollment target
20
Study locations

Study Summary

The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS). The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Worsening (RAW) or Progression Independent of Relapses (PIRA). The study also aims to assess the safety, usability, and satisfaction of the solution. A secondary objective is to determine MSCopilot® Detect's ability to provide early detection of disease changes and predict changes in Expanded Disability Status Scale (EDSS) scores in more patients. Exploratory objectives include evaluating the relationship between MSCopilot® Detect composite and individual scores and other biomarkers such as MRI, soluble glial fibrillary acidic protein (sGFAP), and soluble neurofilament light chain (sNfL). Patients will be able to download the free MSCopilot® Detect app. They will participate in 1 inclusion visit and 3 follow-up visits, scheduled at 6 months, 12 months, and 18 months (an additional visit at 24 months may be scheduled if necessary). Every 3 months, patients will complete validated questionnaires regarding MS symptoms and quality of life and participate in digital tests designed to monitor MS symptom progression. The study will include 336 MS patients and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France

Primary Outcome

The discriminatory ability of the MSCopilot® Detect application in detecting clinically meaningful worsening (disability worsening) based on the revised-MSFC will be evaluated using the Area Under the ROC Curve (AUC) method. Confidence intervals will also be estimated. The minimum significant AUC value will be set at \>0.67, and Confidence Intervals will be calculated. Sensitivity and specificity will also be determined. To validate the estimated AUC values and cutoffs generated by the MSCopilo

Conditions Studied

Interventions

  • DEVICE MSCopilot® Detect mobile application

Study Locations (20)

Other

  • Galina Vorobeychik - Burnaby
  • Mark Freedman - Ottawa
  • St. Michael's Hospital - Toronto
  • Robert Carruthers - Vancouver
  • University Hospital of Southern Denmark - Esbjerg
  • Finn Sellebjerg - Glostrup Municipality
  • Sivagini Prakash - Viborg
  • Hôpital Roger Salengro - Lille
  • Cécile Donzé - Lomme
  • Adil Maarouf - Marseille

California

  • Jennifer Graves - San Diego

Georgia

  • Joash Lazarus Sr. - Atlanta

Illinois

  • Daniel Wynn - Northbrook

Indiana

  • Craig E. Herrman - Indianapolis

Louisiana

  • Jennifer Feng - New Orleans

Missouri

  • Robert Naismith - St Louis

Ohio

  • Aaron Boster - Columbus

Trial Details

FieldValue
Enrollment Target 336 participants
Start Date 2023-09-22
Est. Completion 2027-05-31
Phase NA
Ad scientiam

5 total trials

What the registry record for NCT05816122 still lists

NCT05816122 is an interventional study that assigns participants to a tested intervention. The registered 336 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (42% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which MSCopilot® Detect mobile application is the first listed.

NCT05816122 names 20 study sites across 11 states, led by Other, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT05816122 about?

NCT05816122 is a clinical study titled "MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect". The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS). The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Wor...

What is the current status of trial NCT05816122?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 336 participants. The study started on 2023-09-22. Estimated completion is 2027-05-31.

What conditions does trial NCT05816122 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT05816122?

The interventions under investigation include: MSCopilot® Detect mobile application (DEVICE).

Who is sponsoring clinical trial NCT05816122?

This trial is sponsored by Ad scientiam, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05816122 being conducted?

This trial has 20 study locations across California, Georgia, Illinois, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05816122's enrollment target sits among peer trials

336 53rd of 315 higher than 263 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03947385 · 336 participants · Phase 1

    Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

  • NCT03977207 · 336 participants · NA

    A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients

  • NCT04665206 · 336 participants · Phase 1

    Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

  • NCT05124457 · 336 participants · Phase 2

    DETERMINE: Detemir vs NPH

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05816122, the US trial registry maintained by the National Library of Medicine. NCT05816122 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.